Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $18.42M |
| Gross Profit (TTM) | $-88.86M |
| EBITDA | $-127.49M |
| Operating Margin | -2382.00% |
| Return on Equity | -238.90% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.17 |
| Book Value | $0.09 |
| Price-to-Book | 21.98 |
| Price-to-Sales (TTM) | 11.63 |
| EV/Revenue | 3.051 |
| EV/EBITDA | -8.40 |
| Quarterly Earnings Growth (YoY) | -86.30% |
| Quarterly Revenue Growth (YoY) | -71.50% |
| Shares Outstanding | $111.03M |
| Float | $93.80M |
| % Insiders | 9.65% |
| % Institutions | 82.20% |
Volatility is currently expanding
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued.
